All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma

January 24th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.

Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC

January 24th 2025

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC

January 24th 2025

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC

January 24th 2025

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC

January 24th 2025

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract

January 24th 2025

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC

January 24th 2025

Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer

January 24th 2025

Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.

Pembrolizumab Plus Lenvatinib and Chemo Misses OS End Point in Gastroesophageal Adenocarcinoma

January 24th 2025

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

PET Probe Images Inflammation With High Sensitivity and Selectivity

January 24th 2025

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer

January 24th 2025

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer

January 24th 2025

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer

January 23rd 2025

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

HR-1701 Plus Chemo Reduces Myelosuppression in HER2-Negative Gastric and GEJ Adenocarcinoma

January 23rd 2025

SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer

January 23rd 2025

Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC

January 23rd 2025

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer

January 23rd 2025

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

Fox Chase Cancer Center Scientist Yash Chhabra Honored With NextGen Stars Award From American Association for Cancer Research

January 23rd 2025

Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program, was recently honored with the American Association for Cancer Research’s NextGen Stars Award.

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

January 23rd 2025

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.